In a number of articles published in JAMA Oncology,1,2,3,4,5 conflict of interest disclosures were not reported accurately by José Baselga, MD, PhD. Dr Baselga has written a Letter to the journal6 explaining this inconsistent reporting of potential conflict of interest disclosures. All articles have been corrected online.
Reference
- 1.Ptashkin RN, Mandelker DL, Coombs CC, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors [published online June 5, 2018]. JAMA Oncol. doi: 10.1001/jamaoncol.2018.2297 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Fumagalli D, Venet D, Ignatiadis M, et al. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol. 2016;3(2):227-234. doi: 10.1001/jamaoncol.2016.3824 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448-454. doi: 10.1001/jamaoncol.2015.0830 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Baselga J. Failure to accurately disclose conflicts of interest in articles published in JAMA Oncology [published online October 26, 2018]. JAMA Oncol. doi: 10.1001/jamaoncol.2018.5674 [DOI] [PubMed] [Google Scholar]